As biopharma adapts to a more selective and capital-conscious environment, traditional models of dealmaking are giving way to bold new approaches. From asset-centric spinouts and externalized R&D engines to venture-backed NewCos, pharma is exploring innovative ways to manage pipeline risk, unlock capital efficiency, and accelerate access to cutting-edge science.

This executive-level session brings together leaders from pharma, biotech, and investment to unpack how these evolving strategies are reshaping the partnering landscape. Whether you're structuring your next deal or positioning your company for strategic alignment, this discussion will offer critical insight into the emerging frameworks defining 2025 and beyond.

Session Takeaways:

Inside Pharma’s NewCo Playbook: Why large companies are spinning out assets and co-creating new ventures—and what it means for the ecosystem
Redefining Risk and Ownership: How new partnering models are reshaping capital flow, optionality, and value creation
Execution in a High-Stakes Environment: What’s working in today’s market—and how to be deal-ready amid changing expectations
Strategic Signals for 2025: Key trends and inflection points that

Day Two: Biopharma PartneringWednesday, 1 October 2025